Basket | Login


The AMYPAD Prognostic and Natural History Study has reached its 100th participant consented

Monday 17 June 2019

The Amyloid imaging to prevent Alzheimer’s disease (AMYPAD) project is now half-way through its 5-year project and fully enrolling for both studies, with the Prognostic Natural History Study (PNHS) exceeding 100 participants from 5 active sites, hopefully soon overtaking the Diagnostic and Patient Management Study (DPMS) that has surpassed the 350 mark. The past months have been of great progress in AMYPAD, and major milestones were achieved for the PNHS. The family of recruiting sites is growing so fast with 5/7 wave 1 sites activated:

  • VU medisch centrum, VUmc (Amsterdam, The Netherlands)
  • Barcelonaβeta Brain Research Center, BBRC (Barcelona, Spain)
  • University of Edinburgh, UEDIN (Edinburgh, UK)
  • University of Geneva, UNIGE (Geneva, Switzerland)
  • CHU de Toulouse, CHUT (Toulouse, France).

 238 research participants have been invited to take part, of which 112 consented. A total of 80 participants have been scanned. The team in Edinburgh has now scanned its first participant and Toulouse recently consented their first research participants. Great progress from its start in October last year, recruitment rates are picking up fast and many new sites are being activated thanks to the hard work of logistic teams. The AMYPAD project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. The Joint Undertaking receives support from the European Union’s Horizon2020 research and innovation programme and EFPIA.